<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To assess the incidence and outcome of secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Between 1981 and 1998, the GHSG conducted three trial generations for early, intermediate, and advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> involving a total of 5,411 patients (called HD1 through HD9) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: A total of 46 patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were identified </plain></SENT>
<SENT sid="3" pm="."><plain>The median age at diagnosis of <z:hpo ids='HP_0001909'>leukemia</z:hpo> was 47 years (range, 22 to 79 years) </plain></SENT>
<SENT sid="4" pm="."><plain>Primary therapy was as follows: radiotherapy alone (n = 4); <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, vinblastine, and <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> (ABVD; n = 1); <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, procarbazine, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (COPP)/ABVD or similar (n = 30); <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, procarbazine, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (BEACOPP) baseline (n = 2); and BEACOPP escalated (n = 9) </plain></SENT>
<SENT sid="5" pm="."><plain>Twelve patients developed <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> after salvage therapy, including four patients who developed <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> after high-dose chemotherapy with autologous stem-cell transplantation </plain></SENT>
<SENT sid="6" pm="."><plain>Thirty-six of the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and 10 malignancies were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>After a median observation time of 55 months, incidence of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was 1% </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment for <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was as follows: <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (Ara-C)-containing regimens (6-thioguanin, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> [TAD]/high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> [HAM], HAM, Ida-Ara-C (<z:chebi fb="0" ids="42068">idarubicin</z:chebi> + Ara-C), Ida-Flag (<z:chebi fb="0" ids="42068">idarubicin</z:chebi>, fludarabin, Ara-C, G-CSF), and <z:chebi fb="0" ids="42068">idarubicin</z:chebi>, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi> [ICE]+HAM; n = 11), TAD-chemotherapy (n = 5), other regimens (n = 3), no treatment or supportive care (n = 24), palliative oral chemotherapy (n = 3), and allogeneic stem cell transplantation (n = 9) </plain></SENT>
<SENT sid="9" pm="."><plain>After 24 months of observation, no difference in freedom from treatment failure and overall survival (2% and 8%, respectively) was observed in patients who developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The prognosis of patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> after primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> is poor </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, emphasis should be made to improve initial treatment in an attempt to prevent this complication </plain></SENT>
</text></document>